New drugs in the management of the irritable bowel syndrome

Drugs

Volumn 56, Issue 1, 1998, Pages 11-21

  Farthing, Michael J G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; CODEINE PHOSPHATE; DIAZEPAM; DIPHENOXYLATE; FEDOTOZINE; GRANISETRON; KAPPA OPIATE RECEPTOR AGONIST; LEUPRORELIN; LOPERAMIDE; LOXIGLUMIDE; NALMEFENE; NALOXONE; OCTREOTIDE; ONDANSETRON; OTILONIUM BROMIDE; PAROXETINE; PIBOSEROD; POLYCARBOPHIL CALCIUM; PROKINETIC AGENT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN ANTAGONIST; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; DIET THERAPY; FOOD ALLERGY; GASTROINTESTINAL TRANSIT; HUMAN; IRRITABLE COLON; NUTRITIONAL INTOLERANCE; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDIARRHEALS; BENZYL COMPOUNDS; COLONIC DISEASES, FUNCTIONAL; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRANSIT; GRANISETRON; HUMANS; LEUPROLIDE; MALE; OCTREOTIDE; ONDANSETRON; PROPYLAMINES; RECEPTORS, OPIOID, KAPPA; SEROTONIN ANTAGONISTS;

EID: 0031825438     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856010-00002     Document Type: Review

References (50)

1. Farthing MJG. Irritable bowel, irritable body, irritable brain? BMJ 1995 Jan; 310 171-5
2. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1977; 95: 232-41
3. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978; 11: 653-4
4. Thompson WG, Creed F, Drossman DA, et al. Functional bowel disease and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91
5. Whorwell PJ, McCallum M, Creed FH, et al. Non-colonic features of irritable bowel syndrome. Gut 1986; 27: 37-40
6. Gomborone JE, Dewsnap PA, Libby GW, et al. Community study reveals that dysfunctional illness attitudes in irritable bowel syndrome are not wholly a reflection of patient status [abstract]. Gastroenterology 1993; 104: A513
7. Gomborone JE, Dewsnap PA, Libby GW, et al. Abdominal illness attitudes in irritable bowel syndrome. J Psychosom Res 1995; 39; 227-30
8. Gomborone JE, Dewsnap PA, Libby GW, et al. Selective affective biasing in recognition memory in the irritable bowel syndrome. Gut 1994; 34: 1230-4
9. Gorard DA, Farthing MJG. Intestinal motor function in irritable bowel syndrome. Dig Dis Sci 1994; 12: 72-84
10. Mayer EA, Raybould HE. The role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 1990; 99: 1688-704
11. Kendall GPN, Thompson DG, Day SJ, et al. Inter and intraindividual variations in pressure-volume relations of the rectum in normal subjects and patients with the irritable bowel syndrome. Gut 1990; 31: 1062-8
12. Cook IJ, Van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727-33
13. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39-40
14. Poynard T, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510
15. Sacks HS, Berner J, Reitman D, et al. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 316: 450-5
16. Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic anti-depressant on small intestinal motility in health and in diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995; 40: 86-95
17. Gorard DA, Libby GW, Farthing MJG. 5-hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994; 34: 496-500
18. Whorwell PJ, Priot A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome. Gut 1987; 28: 423-5
19. Guthrie E, Creed F, Dawson D, et al. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450-7
20. Guthrie E, Creed F. The difficult patient: treating the mind and the gut. Eur J Gastroenterol Hepatol 1994; 6: 489-94
21. Young F, Stoneham MD, Petruckevitch A, et al. A population study of food intolerance. Lancet 1994; 343: 1127-30
22. Nanda R, James R, Smith H, et al. Food intolerance and the irritable bowel syndrome. Gut 1989; 30: 1099-104
23. Stefanini GF, Prati E, Albini MC, et al. Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. Am J Gastroenterol 1992; 87: 55-7
24. Stefanini GF, Saggioro A, Alvisi V, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Scand J Gastroenterol 1995; 30: 535-41
25. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-8
26. Schutze K, Brandstatter G, Dragosics B, et al. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 387-94
27. Chami TN, Whitehead WE, Bennett C, et al. Treatment of constipation-predominant irritable bowel syndrome (IBS-C) with the opioid antagonist nalmefene glucuronide (NG) [abstract]. Am J Gastroenterol 1993; 88: 1568
28. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmcol Ther 1993; 7: 87-92
29. Junien JL, Riviere P. The hypersensitive gut - peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995; 9: 117-26
30. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Dig Dis Sci 1995; 40: 2244-8
31. Farthing MJG. 5-hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand J Gastroenterol 1991; 26: 92-100
32. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 175-80
33. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 543-51
34. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharmacol Ther 1996; 10: 595-9
35. 4 antagonism in irritable bowel syndrome (IBS): effect of SB-207266A on rectal sensitivity and small bowel transit [abstract]. Gut 1997; 4 (Suppl 3): A26
36. Madrazo I, Franco-Bourland RE, Leon-Maza VM, et al. Intraventricular somatostatin-14, arginine vasopressin, and oxytocin: analgesic effect in a patient with intractable cancer pain. Appl Neurophysiol 1987; 50: 427-31
37. Penn RD, Paice JA, Kroin JS. Intrathecal octreotide for cancer pain [letter]. Lancet 1990; 335: 738
38. Mollenholt P, Post C, Paulsson I, et al. Intrathecal and epidural somatostatin in rats: can anti-nociception, motor effects and neurotoxicity be separated? Pain 1990; 43: 363-70
39. ODonnell LJD, Watson AJM, Cameron D, et al. Effect of octreotide on mouth-to-caecum transit time in healths subjects and the irritable bowel syndrome. Aliment Pharmacol Ther 1990; 4: 177-82
40. Talley NJ, Turner I, Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; 11: 1114
41. Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993; 104: 1390-7
42. McQuay HJ, Moore RA. Anti-depressants and chronic pain. BMJ 1997; 314: 763-4
43. Harrison G. New or old anti-depressants? New is better. BMJ 1994; 309: 1280-2
44. Wood JD. Efficacy of leuprolide in treatment of the irritable bowel syndrome. Dig Dis Sci 1994; 39: 1153-4
45. Mathias JR, Clench MH, Reeves-Darby VG, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Dig Dis Sci 1994; 39: 1155-62
46. Kamm MA, Farthing MJG, Lennard-Jones JE. Bowel function and transit rate during the menstrual cycle. Gut 1989; 30: 605-8
47. Mathias JR, Clench MH, Roberts PH, et al. Effect of leuprolide acetate in patients with functional bowel disease: long-term follow-up after double-blind, placebo-controlled study. Dig Dis Sci 1994: 1164-70
48. Mayer BM, Werth BA, Beglinger C, et al. Role of cholecystokinin regulation of gastrointestinal motor functions. Lancet 1989; 11: 12-5
49. Cann PA, Rovati LC, Smart H, et al. Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome: a pilot multicentre clinical study [abstract]. Gastroenterology 1993; 104: A486
50. Capurso L, Del Sette F, Tarquini M, et al. Octylonium bromide plus diazepam versus diazepam or octylonium bromide alone in the treatment of irritable bowel syndrome: an open-controlled clinical trial. Curr Ther Res 1992; 52: 368-77